8-K: InMed Pharmaceuticals Announces 1-for-20 Share Consolidation to Regain Nasdaq Compliance

InMed Pharmaceuticals will consolidate its shares on a 1-for-20 basis to meet Nasdaq's minimum bid price requirement.

Summary

• InMed Pharmaceuticals is implementing a share consolidation, also known as a reverse stock split, at a ratio of 1-for-20.
• This means that every 20 existing shares will be combined into one new share.
• The primary reason for this consolidation is to regain compliance with Nasdaq's listing rules, specifically the minimum bid price requirement of $1.00 per share.
• The consolidation will reduce the number of outstanding shares from approximately 14,361,550 to about 718,078 on a non-diluted basis.
• The percentage ownership of each shareholder will remain the same after the consolidation.
• The exercise price and number of shares issuable under outstanding stock options, warrants, and other convertible securities will be adjusted proportionally.
• Fractional shares will not be issued; any fraction less than half a share will be cancelled, and fractions of half a share or more will be rounded up to one whole share.
• The consolidation is expected to be effective on November 14, 2024, with trading on a post-consolidation basis starting on November 15, 2024.
• The company's trading symbol 'INM' will remain the same, but the shares will have a new CUSIP number of 457637700 and a new ISIN number of CA4576377002.

Sentiment

Score: 4

Explanation: The sentiment is negative as the share consolidation is a result of the company's share price falling below the required minimum. While necessary for compliance, it is not a positive development for investors.

Positives

• The share consolidation is a necessary step to maintain the company's listing on the Nasdaq.
• The consolidation will not change the percentage ownership of existing shareholders.
• The company is taking proactive steps to address compliance issues.

Negatives

• The share consolidation is a result of the company's share price falling below the Nasdaq minimum bid price requirement.
• Share consolidations can sometimes be perceived negatively by the market.

Risks

• There is a risk that the share consolidation may not be sufficient to maintain compliance with Nasdaq listing rules.
• The company's share price may continue to be volatile.
• The company's ability to raise capital may be affected by the share consolidation.

Future Outlook

The company anticipates that the consolidation will be deemed effective by Nasdaq on November 14, 2024, and the post-Consolidation Common Shares are anticipated to begin trading on a Consolidation-adjusted basis on the Nasdaq Capital Market commencing at the market open on November 15, 2024.

Management Comments

• The company's board of directors approved the share consolidation to regain compliance with Nasdaq listing rules.

Industry Context

Share consolidations are a common mechanism for companies to regain compliance with stock exchange listing requirements when their share price falls below the minimum threshold. This action is not uncommon in the pharmaceutical industry, especially for smaller companies with volatile stock prices.

Comparison to Industry Standards

• Share consolidations are a standard practice for companies facing delisting due to low share prices.
• Many small-cap biotech companies have used reverse stock splits to maintain their listing on major exchanges.
• For example, companies like Athersys and Ocugen have recently undergone reverse stock splits to maintain Nasdaq compliance.
• The 1-for-20 ratio is within the typical range for such consolidations, which can vary from 1-for-2 to 1-for-50 or more.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they hold, but their percentage ownership will remain the same.
• The share consolidation is intended to maintain the company's listing on the Nasdaq, which is important for investor confidence.

Next Steps

• The company will implement the share consolidation.
• The company will begin trading on a post-consolidation basis on November 15, 2024.
• Registered shareholders will receive a letter of transmittal with instructions.

Key Dates

Keywords

share consolidation, reverse stock split, Nasdaq compliance, minimum bid price, INM, stock options, warrants, convertible securities